Stockscreener 앱 받기
1.08
9.90%
0.0973
전일 마감가:
$0.9827
열려 있는:
$1
하루 거래량:
6.00M
Relative Volume:
6.41
시가총액:
$206.03M
수익:
$4.71M
순이익/손실:
$-58.01M
주가수익비율:
-1.3116
EPS:
-0.8234
순현금흐름:
$-46.68M
1주 성능:
+10.42%
1개월 성능:
+13.08%
6개월 성능:
-4.42%
1년 성능:
-14.29%
1일 변동 폭
$0.997
$1.08
1주일 범위
$0.9574
$1.08
52주 변동 폭
$0.90
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
명칭
Lucid Diagnostics Inc
전화
212 949 4319
주소
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.08 | 206.03M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 개시 | BTIG Research | Buy |
| 2021-11-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Needham | Buy |
Lucid Diagnostics Inc 주식(LUCD)의 최신 뉴스
Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lucid Diagnostics Inc (LUCD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lucid Diagnostics Inc (LUCD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lucid Diagnostics Inc (LUCD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026. - marketscreener.com
Lucid Diagnostics misses on revenue, but 2026 growth outlook lights up bull case - MSN
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case - Benzinga
LUCD Maintained by Ascendiant Capital -- Price Target Raised to $9.25 - GuruFocus
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results - Yahoo Finance
Lucid Diagnostics Q1 2026 Earnings: EPS Miss Widens as Company Reports Wider-Than-Expected LossProfit Inflection Point - newsline.com
LUCD Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue Stage ChallengesRevenue Warning Signal - The Legal Advocate
LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD) - ChartMill
LUCD - Finviz
Lucid Diagnostics (LUCD) Surges 7% as Momentum Builds Near Key ResistanceTurnaround Stocks - The Legal Advocate
Lucid Diagnostics Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Firm Advances Commercial Rollout - The Legal Advocate
Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market - Stock Titan
Lucid Diagnostics (LUCD) Rallies +1.30% as Bulls Target $1.02 2026-05-19Dividend Growth Stocks - The Legal Advocate
Lucid Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-05-17 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates - MSN
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ... By GuruFocus - Investing.com Canada
Upcoming Events - FinancialContent
Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
BTIG Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $2.5 - Moomoo
PAVmed (PAVM) Q1 2026 Earnings Transcript - AOL.com
PAVmed (PAVM) Q4 2025 Earnings Transcript - The Globe and Mail
PAVmed Reports Q1 2026 Financial Results, Highlights Progress in Veris Health FDA Submission and Lucid Diagnostics Commercial Expansion - Minichart
Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q1 2026 Earnings Conference - 富途牛牛
PAVmed Reports Wider-than-Expected Q1 2026 Loss - AlphaStreet
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains By Investing.com - Investing.com Australia
Q1 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call Transcript - Insider Monkey
PAVmed (NASDAQ: PAVM) Q1 2026 results, losses and cash position - Stock Titan
PAVmed Q1: cancer test and implantable monitor push toward coverage, FDA - Stock Titan
Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD) - The Globe and Mail
Lucid says $44.8M pro forma cash extends runway well into 2027 as it awaits Medicare LCD - MSN
Lucid Diagnostics Inc.Common Stock (NQ: LUCD - FinancialContent
PAVmed Inc.Series Z Warrant (NQ: PAVMZ - FinancialContent
Lucid Diagnostics Earnings Call Balances Progress, Pressure - TipRanks
PAVmed Reports Business Expansion and Financial Update - Intellectia AI
PAVmed (NASDAQ: PAVM) posts Q1 2026 loss and flags going concern risks - Stock Titan
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics Releases Q1 2026 Financial Results - AlphaStreet
LUCD Q1 2026 Earnings Transcript - The Globe and Mail
Lucid Diagnostics Q1 Earnings Call Highlights - Yahoo Finance
LUCD: Q1 revenue reached $1.3M on 3,177 tests, with cash runway extended and Medicare approval pending - TradingView
Lucid Diagnostics Reports Q1 2026 Financial Results: $1.3M Revenue, Strong Cash Position, and Medicare Reimbursement Milestone Progress - Minichart
Lucid Diagnostics Inc (LUCD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lucid Diagnostics Inc 주식 (LUCD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
Aug 20 '25 |
Buy |
1.02 |
100,000 |
101,840 |
665,443 |
0.93%
자본화:
|
볼륨(24시간):